Skip to main content

Table 1 Clinical information of serum of normal control and patients with various cancers

From: Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

Breast carcinoma

Non-small Cell Lung Cancer (NSCLC)

Colorectal carcinoma

Kidney carcinoma

Normal control

Characteristics

Characteristics

Characteristics

Characteristics

Characteristics

No. of samples

197

No. of samples

111

No. of samples

64 (Rectal 14)

No. of samples

30

No. of samples

100

Female

197

Male

50

Male

33 (Rectal 7)

Male

17

Male

50

Mean age (years)

48.54 ± 18.43 (20–91)

Female

61

Female

31 (Rectal 7)

Female

13

Female

50

Stage I

66 (35:31)*

Mean age (years)

41 ± 10.39 (41–85)

Mean age (years)

63.84 ± 12.20 (39–78)

Mean age (years)

55.07 ± 11.22 (34–76)

Male mean age (years)

44.54 ± 14.85 (20–76)

Stage II

70 (37:33)

Stage I

39 (IA 19, IB 20)

Stage I

6

Stage I

26

Female mean age (years)

43.70 ± 14.95 (18–71)

Stage III

61 (34–27)

Stage II

32 (IIA 16, IIB 16)

Stage II

36 (Rectal 7)

Stage II

4

Female/Male

44.12 ± 14.83

Lobular type

106

Stage III

30 (IIIA 21, IIIB 90)

Stage III

22 (Rectal 7)

Mean age (years)

(18–76)

Ductal type

91

Stage IV

10

      
  1. All sera obtained from Caucasian White.
  2. *First and second values are # of lobular and ductal carcinoma breast cancer.